| abstract |
The invention relates to compounds of formula (I) wherein A 1 , R 1 , R 2 , R 3 , R 4 and R 5 are defined in the description and in the claims, which are preferential inhibitors of the cysteine protease cathepsin, in particular of the cysteine protease cathepsin S or L, making them useful as medicaments, particularly in the treatment of diabetes, atherosclerosis, abdominal aortic aneurysm, peripheral arterial disease or diabetic nephropathy. |